Aranscia

PGx testing for DPD deficiencies will help them avoid critical or fatal side effects due to dangerously high or toxic accumulations of these drugs in the patient’s liver. According to the new FDA labeling released in October 2025, providers should include pharmacogenomic testing (PGx) before beginning treatment with the chemotherapy drug capecitabine: https://lnkd.in/gQwzVtz2 Oncologists need to adapt their workflows to assess the risks posed by this warning label. This means identifying patients for potentially fatal drug-gene risks, streamlining the test-ordering workflow, and delivering actionable reports at the point of care – all before starting patients on their selected therapy whenever clinically possible. Aranscia has solutions at the ready to fast-track FDA compliance initiatives.        1. The AccessDx Laboratory PGx Profile already includes DPYD variants – and AccessDx is actively working with oncologists to support the adoption of DPYD testing with fast-turnaround times and integrated ordering workflows.       2. Aranscia’s clinical pharmacists and PGxperts™ immediately validated this explicit guidance update and incorporated the revised warning information into the YouScript® knowledgebase.       3. The Spesana and 2bPrecise® platforms, plus YouScript clinical decision support, deliver both pre- and post-test guidance for DPYD within existing provider-centric workflows. How can we help your organization today? https://lnkd.in/g8ruitTf

During National Pharmacy Week - an annual observance hosted by ASHP - we invite you to join Aranscia in recognizing those in the pharmacy world who make invaluable contributions to patient care across the healthcare space. #PharmacyWeek #NationalPharmacyWeek #PatientCare

The FDA has updated the black box warning for Xeloda® to require DPYD testing before starting treatment. This marks a significant step forward for patient safety and the broader adoption of pharmacogenomic (PGx) testing in oncology. For years, leaders across the industry, including Aranscia's Houda Hachad and Kristine Ashcraft, have championed the need for routine DPYD testing prior to initiating fluoropyrimidine based chemotherapy. Their collaboration with pharmacogenomic expert groups and Advocates for Universal DPD/DPYD Testing has been instrumental in driving regulatory change and raising awareness about the clinical value of PGx-informed care. This update represents a multi-faceted win for patient safety. #pgx #oncology #patientsafety #DPYD #precisionmedicine #precisiononcology

Don't wait longer than you need to. Research has shown that the average delay is 11 years between the onset of mental health symptoms and treatment seeking. With time being of the essence, particularly in mental health, let Aranscia's suite of precision medicine tools help you get your patients on the right medications, faster. #Pharmacogenomics #MentalHealth #MentalIllnessAwarenessWeek #MIAW #PGx #PrecisionMedicine #PersonalizedMedication

Join Aranscia in bringing attention to suicide prevention during September - an important month for suicide awareness and prevention. • September is National Suicide Prevention Month • September 7-13 is National Suicide Prevention Week • September 10 is World Suicide Prevention Day Studies have shown ties between mental health, suicide, and pharmacogenomics. A simple PGx test can help providers identify the most appropriate medication for their patients, reduce medication failure and switching, and reduce overall time to treatment. #SuicidePrevention #MentalHealth #SuicideAwareness #PGx #Pharmacogenomics #PersonalizedMedication

Aranscia Insights - our quarterly newsletter - is now live for Q3 2025! This quarter covers everything from Alzheimer's and dementia, Tardive Dyskinesia, DPYD testing, polypharmacy, and more! #AccessDxInsights #LTPAC #EndALZ #Dementia #TardiveDyskinesia #DPYD #Polypharmacy #PrecisionMedicine #PersonalizedMedicine

Alzheimer's and Brain Awareness Month is ending - but the conversation continues. With 1 in 9 older adults having Alzheimer's Disease, it is imperative to discuss and understand dementia prevention, intervention, and care - from acknowledging preventable risk factors to testing that measures p-tau 217. #EndAlz #AlzheimersDisease #Dementia #Alzheimers

"For clinicians, PGx offers a powerful opportunity to adopt a “top-down” approach to prescribing. Instead of reacting to adverse events after they occur, doctors can proactively use genetic insights to avoid potentially harmful drug-gene interactions before writing a prescription. Robust integration into clinical workflows is essential." - Joel Diamond, CMO, Aranscia Read "Beyond the Allergy Bracelet: Why Genes Hold the Key to Real Medication Safety" in Answers Media Network: https://lnkd.in/eMK3cd-u #MedicationSafety #MedicationManagement #Pharmacogenomics #PGx #PersonalizedPrescribing #AdverseDrugEvents #ADEs

June is Alzheimer's and Brain Awareness Month. Over 55 million people live with Alzheimer's or another dementia, and nearly 66% of Americans have at least one potential major risk factor for dementia. We are proud to be working alongside Neurogen Biomarking to support their mission to accelerate early detection for Alzheimer's Disease. Learn more about our partnership in our announcement press release: https://lnkd.in/gMbbmehB #ENDALZ #AlzheimersAwareness #DementiaAwareness

Today, Neurogen Biomarking and Aranscia announced a partnership in which Aranscia's technical and laboratory resources will help deliver clinical insights and HIPAA-compliant connectivity for the Neurogen Biomarking ecosystem. This partnership includes support from two Aranscia companies, AccessDx Laboratory and 2bPrecise. "We're proud to partner with Neurogen on its mission to accelerate early detection and interventionist care in the fight against Alzheimer's disease, which has become all too personal for millions of Americans and their families," said Bryon Cipriani, CEO of Aranscia. Read the full press release here: https://lnkd.in/gMbbmehB #PrecisionMedicine #AlzheimersDisease